On May 29, 2025 NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer immunotherapies, reported the company has regained its status as a privately-held company, separating from its recent merger with INVO Bioscience. This strategic decision enables NAYA Therapeutics to optimize its portfolio development strategy for value maximization and market attractiveness as it advances towards clinical development milestones for its portfolio of first and potential best-in-class candidates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NAYA is harnessing the power of its innovative clinical candidates towards two priority franchises: hepatocellular carcinoma (HCC), where 70-85% of candidates for systemic therapy are non-responders to checkpoint inhibitors, and multiple myeloma, with a large and rapidly-growing market in need of new therapies to address the limitations of daratumumab and T-cell engagers.
"We’re incredibly excited about the clinical potential of NAYA’s first and best-in-class cancer immunotherapeutics and their advancement towards near-term clinical milestones," commented NAYA’s CEO, Dr. Daniel Teper. "Enrollment of HCC patients for Phase I/II clinical trials of NY-303, which shows unique potential to unlock the biology of checkpoint inhibitor non-responders, is expected in 2025. Next, we are aiming to initiate Phase I/II clinical trials of NY-500, positioned to be the first PD-1/VEGF to market in HCC, in 2026. Finally, NY-338, which shows a differentiated profile to daratumumab and T-cell engagers, is anticipated to commence enrolling patients in its Phase I/II clinical trials in multiple myeloma in 2026. In addition, we are initiating the development of a novel radioimmunotherapeutic for HCC to further strengthen our therapeutic franchise. As we accelerate the advancement of these breakthrough therapies to market, NAYA is positioned to rapidly unlock its valuation and partnership attractiveness."
(Press release, NAYA Biosciences, MAY 29, 2025, View Source [SID1234670431])